Skip to main content

Advertisement

SpringerLink
Log in

Autoimmune hepatitis

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Autoimmune hepatitis (AIH) is a progressive inflammatory hepatitis of unknown etiology that is responsive to immunosuppressive therapy. The diagnosis of AIH should be guided by the descriptive criteria and scoring system set forth by the International Autoimmune Hepatitis Group. Standard therapy is prednisone with or without azathioprine (AZA). Combination therapy with prednisone and AZA is preferred, as it allows treatment with lower individual doses of each drug and is thus associated with fewer side effects. Treatment goals include complete biochemical, clinical, and histologic remission. Treatment outcomes include complete remission with or without relapse, incomplete response, or treatment failure. Treatment withdrawal, once remission has been attained, may be associated with relapse of disease. Recurrent relapse may be addressed with long-term, lower dose maintenance treatment with prednisone or AZA. Incomplete response is addressed by attempting high-dose immunosuppressive regimens or by considering investigational medical regimens. Treatment failure is also addressed by considering investigational medical regimens. Medication toxicity is addressed with dose reduction or drug discontinuation. Should the patient progress to decompensated cirrhosis, liver transplantation is an effective treatment for AIH. Calcium and vitamin D supplementation, a wellbalanced diet, and exercise are advocated in patients with AIH. Cyclosporine, mycophenolate mofetil, and tacrolimus are promising agents among the new therapies for autoimmune hepatitis. Unfortunately, newer therapeutic agents have been studied in small numbers. Larger, controlled treatment trials are needed to expand the repertoire of therapeutics to treat patients with fewer side effects and to provide alternatives for patients who are refractory to conventional therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Johnson PJ, McFarlane IG: Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18: 998–1005.

    Article  PubMed  CAS  Google Scholar 

  2. Ludwig J, McFarlane IG, Rakela J: International Working Party Report: Terminology of chronic hepatitis. Am J Gastro 1995, 90: 181–189.

    Google Scholar 

  3. Czaja AJ, Freese DK: AASLD Practice Guidelines-Diagnosis and treatment of autoimmune hepatitis. Hepatology, 2002, 36: 479–497. Practice guidelines that summarize recommendations.

    Article  PubMed  Google Scholar 

  4. Medina J, Garcia-Buey L, Moreno-Otero R: Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Aliment Pharmacol Ther, 2003, 17: 1–16.

    Article  PubMed  CAS  Google Scholar 

  5. Boberg KM, Aadland E, Jahnsen J, et al.: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastro 1998, 33: 99–103.

    Article  CAS  Google Scholar 

  6. Nishioka M, Morshed SA, McFarlane IG: Geographical variation in the frequency and characteristics of autoimmune liver disease, in Autoimmune liver diseases, W.R. Krawitt EL, Nishioka M, Editor. Elsevier: Amsterdam. 1998, 413–424.

    Google Scholar 

  7. Lim KN, Casanova RL, Boyer TD, et al.: Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastro 2001, 96: 3390–3394.

    Article  CAS  Google Scholar 

  8. Schalm SW, Korman MG, Summerskill WH, et al.: Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977, 22: 973–980.

    Article  PubMed  CAS  Google Scholar 

  9. Czaja AJ, Davis GL, Ludwig J, et al.: Autoimmune features as determinants of prognosis in steroidtreated chronic active hepatitis of uncertain etiology. Gastroenterology 1983, 85: 713–717.

    PubMed  CAS  Google Scholar 

  10. Czaja AJ, Davis GL, Ludwig J, Taswell HF: Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984, 4: 622–627.

    Article  PubMed  CAS  Google Scholar 

  11. Alvarez F, Berg PA, Bianchi FB, et al.: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31: 929–938.

    Article  PubMed  CAS  Google Scholar 

  12. Roberts SK, Therneau T, Czaja AJ: Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996, 110: 848–857.

    Article  PubMed  CAS  Google Scholar 

  13. Seaberg EC, Belle SH, Beringer KC, et al.: Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS liver transplant registry. In Clinical Transplants 1998. Edited by Cecka JM. Los Angeles: UCLA Tissue Typing Laboratories; 1999: 17–37.

    Google Scholar 

  14. CzajaAJ, Francesco BB, Carpenter HA, et al.: Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005, 41: 207–215. Expert review of current investigational challenges in autoimmune hepatitis.

    Article  PubMed  Google Scholar 

  15. Czaja AJ, Wolf AM, Baggenstoss AH: Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981, 80: 687–692.

    PubMed  CAS  Google Scholar 

  16. Soloway RD, Summerskill WHJ, Baggenstoss AH, et al.: Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972, 63: 820–833.

    PubMed  CAS  Google Scholar 

  17. Schalm SW, Ammon HV, Summerskill WH: Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976, 8: 221–227.

    PubMed  CAS  Google Scholar 

  18. Czaja AJ, Menon KV, Carpenter HA: Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002, 35: 890–897.

    Article  PubMed  CAS  Google Scholar 

  19. Hayash M, Keeffe EB, Krams SM, et al.: Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg 1998, 4: 208–214.

    Article  Google Scholar 

  20. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001, 44: 1496–1503.

    Article  Google Scholar 

  21. Czaja AJ: Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990, 11: 1044–1049.

    Article  PubMed  CAS  Google Scholar 

  22. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH: Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975, 16: 876–883.

    PubMed  CAS  Google Scholar 

  23. Connell WR: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343: 1249–1252.

    Article  PubMed  CAS  Google Scholar 

  24. Devlin J, Donaldson P, Portmann B: Recurrence of autoimmune hepatitis following liver transplantation. Liver Transpl Surg 1995, 1: 162–165.

    Article  PubMed  CAS  Google Scholar 

  25. Gotz G, Neuhaus R, Bechstein WO, et al.: Recurrence of autoimmune hepatitis after liver transplantation. Transplant Proc 1999, 31: 430–431.

    Article  PubMed  CAS  Google Scholar 

  26. Milkiewicz P, Hubscher SG, Skiba G, et al.: Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999, 68: 253–256.

    Article  PubMed  CAS  Google Scholar 

  27. Ratziu V, Samuel D, Sebagh M, et al.: Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999, 30: 131–141.

    Article  PubMed  CAS  Google Scholar 

  28. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al.: Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001, 7: 302–310.

    Article  PubMed  CAS  Google Scholar 

  29. Richardson PD, James PD, Ryder SD: Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000, 33: 371–375.

    Article  PubMed  CAS  Google Scholar 

  30. Devlin SM, Swain MG, Urbanski SJ, Burak KW: Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol, 2004, 18: 321–326.

    PubMed  Google Scholar 

  31. Fernandes NF, Redeker AG, Vierling JM, et al.: Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastro 1999, 94: 241–248.

    Article  CAS  Google Scholar 

  32. Van Thiel DH, Wright H, Carroll P, et al.: Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastro 1995, 90: 771–776.

    Google Scholar 

  33. Aqel BA, Machicao V, Rosser B, et al.: Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004, 38: 805–809.

    Article  PubMed  CAS  Google Scholar 

  34. Heneghan MA, Rizzi P, McFarlane IG, et al.: Low dose tacrolimus as treatment of severe autoimmune hepatitis: potential role in remission induction. Gut 1999, 44: A61.

    Google Scholar 

  35. Danielsson A, Prytz H: Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994, 8: 585–590.

    Article  PubMed  CAS  Google Scholar 

  36. Czaja AJ, Lindor KD: Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000, 119: 1312–1316.

    Article  PubMed  CAS  Google Scholar 

  37. Nakamura K, Yoneda M, Yokohama S, et al.: Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998, 13: 490–495.

    PubMed  CAS  Google Scholar 

  38. Czaja AJ, Carpenter HA, Lindor KD: Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999, 30: 1381–1386.

    Article  PubMed  CAS  Google Scholar 

  39. Pratt DS, Flavin DP, Kaplan MM: The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996, 110: 271–274.

    Article  PubMed  CAS  Google Scholar 

  40. Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A, et al.: Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999, 91: 630–638.

    PubMed  CAS  Google Scholar 

  41. Burak KW, Urbanski SJ, Swain MG: Successful treatment of refractory type I autoimmune hepatitis with methotrexate. J Hepatol 1998, 29: 990–993.

    Article  PubMed  CAS  Google Scholar 

  42. Venkataramani A, Jones MB, Sorrell MF: Methotrexate therapy for refractory chronic active autoimmune hepatitis. Am J Gastro 2001, 96: 3432–3433.

    Article  CAS  Google Scholar 

  43. Kanzler S, Gerken G, Dienes HP, et al.: Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis-report of three cases. Z Gastroenterol 1997, 35: 571–578.

    PubMed  CAS  Google Scholar 

  44. Kerkar N, Dugan C, Rumbo C, et al.: Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplantation 2005, 5: 1085–1089.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hepatology, Northwestern University, Feinberg School of Medicine, 675 N. St. Clair, Suite # 15-250, 60611, Chicago, IL, USA

    Steven L. Flamm MD

Authors
  1. Joseph Ahn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven L. Flamm MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahn, J., Flamm, S.L. Autoimmune hepatitis. Curr Treat Options Gastro 8, 481–492 (2005). https://doi.org/10.1007/s11938-005-0035-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-005-0035-7

Keywords

Search

Navigation